Journals / Tıp Araştırmaları Dergisi / 2013 / Cilt: 11 - Sayı: 3

Gene Variations of Proprotein Convertase Subtilisin/Kexin- 9 (PCSK9) Enzyme in Atherosclerosis

Proprotein Konvertaz Subtilisin/Keksin-9 (PCSK9) Enzim Genindeki Varyasyonlar ve Ateroskleroz

Pages
143–150
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Current areas of interest and invastigation focus on gene variants and protein functions of PCSK9 enzyme as a risk factor for atherosclerosis because of its major effects on LDL metabolism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Atherosclerosis is a multifactorial disease resulted from the interaction of numerous genetic and environmental factors.
📊
Key Findings & Data:Proprotein convertase subtilisin/kexin 9 (PCSK9) is a secreted serine protease that regulates cholesterol homoeostasis by inducing post-translational degradation of LDLR.
💡
Conclusion & Impact:Current areas of interest and invastigation focus on gene variants and protein functions of PCSK9 enzyme as a risk factor for atherosclerosis because of its major effects on LDL metabolism.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Atherosclerosis is a multifactorial disease resulted from the interaction of numerous genetic and environmental factors. Given that plasma lipids are major risk factors for atherosclerosis, genes involved in lipoprotein synthesis and metabolism are considered excellent candidate genes for susceptibility to atherosclerosis. The plasma low-density lipoprotein (LDL) level is the major determinant of the risk of atherosclerosis. The LDL receptor (LDLR) which is a surface membrane protein plays a major role in the removal of atherogenic LDLcholesterol particles from the blood. Proprotein convertase subtilisin/kexin 9 (PCSK9) is a secreted serine protease that regulates cholesterol homoeostasis by inducing post-translational degradation of LDLR. Several mutations have been identified in pcsk9 gene that result in increase/decrease LDLR level. Mutations in the PCSK9 gene have been associated with both hypocholesterolemia and hypercholesterolemia through 'loss-offunction' and 'gain-of-function' mechanisms, respectively. Current areas of interest and invastigation focus on gene variants and protein functions of PCSK9 enzyme as a risk factor for atherosclerosis because of its major effects on LDL metabolism.

Özet

Ateroskleroz çok sayõda genetik ve çevresel faktörün etkileşimiyle gelişen multifaktöriyel bir hastalõktõr. Plazma lipidleri ateroskleroz gelişiminde başlõca risk faktörleri arasõnda yer aldõğõndan lipoprotein sentez ve metabolizmasõnda yer alan genler ateroskleroza yatkõnlõkta önemli aday genlerdir. Plazma düşük yoğunluklu lipoprotein (LDL) düzeyi ateroskleroz gelişimi için önemli belirteçlerden biridir. LDL-reseptörü (LDLR) aterojenik LDL-kolesterolün kandan uzaklaştõrõlmasõnda önemli rol oynar. Bir serin proteaz enzimi olan Proprotein konvertaz subtilisin/keksin 9 (PCSK9) LDLR'nün translasyon sonrasõ degrasyonuna neden olarak kolesterol homeostazõnõ düzenlemektedir. PCSK9 genindeki bazõ mutasyonlar LDLR düzeyinde artma/azalma ile sonuçlandõğõ tanõmlanmõştõr. PCSK9 geninde fonksiyon kazanõmõ/kaybõna sebep olan mutasyon ve polimorfizmlerin hiperkolesterolemi/ hipokolesterolemi ile ilişkili olduğu bildirilmiştir. Son araştõrmalar aterosklerozda risk faktörü olarak LDL metabolizmasõ üzerindeki önemli etkileri nedeniyle PCSK9 gen varyantlarõ ve proteinfonksiyonlarõ üzerine yoğunlaşmõştõr.

🔖

Cite This Article

TEKER, A. A., İSBİR, T., AYDOĞAN, H. Y. (2013). Gene Variations of Proprotein Convertase Subtilisin/Kexin- 9 (PCSK9) Enzyme in Atherosclerosis. Tıp Araştırmaları Dergisi, Cilt: 11 - Sayı: 3, 143–150. https://ajindex.com/articles/361841

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Farmer JA, Gotto A. Risk factor for coronary artery disease. In: Braunwald Heart Disease A Textbook of cardiovascular medicine. 4th ed An HBJ International Edition, Volume 1, Chapter 37, 1992;1125-55
  2. Ross R. The pathogenesis of atherosclerosis. In: Braunwald Heart Disease A Textbook of Cardiovascular Medicine. 4th edition An HBJ International Edition, Volume 1,Chapter 36, 1992;1106-24, 3. Takahashi K, Takeya M, Sakashita N. Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals. Med Electron Microsc 2002; 35:179-203
  3. Fuster V. Mechanisms leading to myocardial infarction: Insights from Studies of Vascular Biology. Circulation 1994; 90(4):2126-46
  4. Onat A, Yazıcı M, Sarı ø. et al. TEKHARF 2003 yılı tarama takibi: Öüm ve koroner olaylara iliúkin sonuçlar úehirlilerde mortalitenin azaldı÷ına iúaret. Türk Kardiyol Dern Arú 2003;31:762-69
  5. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992; 70: 3H-9H, 7. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986; 256: 2835-2838
  6. Castelli WP, Gasrrison RJ, Dawber TR, McNamara PM, Feinleib M, Kannel WB. The filter cigarette and coronary heart disease:The Framingham study. Lancet 1982; 2: s109- 113, 9. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989; 79: 8- 15
  7. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979; 59:8-13
  8. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: The Framingham study. Circulation 1980;61:1179- 1182
  9. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: New perspectives based on the Framingham study. Ann Intern Med 1979; 90:85-91
  10. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, lowdensity lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882- 888
  11. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: Role of lipoprotein cholesterols. Am J Cardiol 1980; 46: 649- 654
  12. Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCS